Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Rosstat announces an increase in the prices of several VED-listed medicines.
- By Newsdesk
- Russia
- Mar 23, 2023
Rosstat (the Federal State Statistics Service) has reported a price increase for several VED-listed medicines in February 2023. Furosemide (3.7%), ibuprofen (1.5%), and acetylsalicylic acid (1.4%) had the highest price increases, with an average price increase of 0.3%. Ascorbic acid, omeprazole, drotaverine, sodium chloride, amoxicillin with clavulanic acid, oseltamivir, and colecalciferol prices all rose by 0.7% to 1.3%.
According to Rosstat, the price of some goods has decreased. Grippferon (1%), Suprastin (0.7%), hydrogen peroxide (0.6%), Azithromycin (0.5%), Smecta (0.4%), and Xarelto (0.4%).
Boris Titov, the Russian Federation's business ombudsman, had recommended developing measures that would not violate entrepreneurs' rights and would eliminate the need to sell VED at prices lower than the purchase price, but the Antimonopoly Service saw this as an attempt by market participants to circumvent the current pricing system.